Using AI to Advance Validated Real-World Evidence

Key Takeaways

• AI converts plain questions into reproducible real‑world evidence in minutes
• Early‑stage RWE boosts confidence for regulatory and market‑access decisions
• Transparent analytics reduce risk and accelerate rare‑disease drug development
• HealthVerity’s platform links de‑identified data for rapid feasibility studies
• Leaders emphasize iterative research cycles across product lifecycle

Pulse Analysis

Artificial intelligence is reshaping how biopharma teams generate real‑world evidence at the earliest stages of drug development. Traditional RWE projects often require weeks of data wrangling and opaque statistical pipelines, creating bottlenecks that delay feasibility assessments and increase financial risk. By leveraging AI‑powered data integration and natural‑language processing, companies can translate plain‑language research questions into structured queries, delivering reproducible analyses in minutes. This speed enables rapid hypothesis testing, more frequent iteration, and clearer documentation of analytic methods, which regulators and payers increasingly demand.

HealthVerity’s platform, showcased by CEO Andrew Kress, exemplifies the new paradigm. The solution aggregates de‑identified claims, electronic health records and pharmacy data into a linked, queryable ecosystem that supports feasibility studies, patient‑journey mapping and health‑economic modeling. Speakers from Chiesi USA, Argenx and Medeloop illustrated how rare‑disease teams use the technology to identify ultra‑small cohorts, assess unmet‑need, and generate evidence that informs both clinical trial design and market‑access dossiers. The ability to produce transparent, auditable outputs reduces reliance on proprietary black‑box models and builds confidence across cross‑functional stakeholders.

The broader industry impact is significant. Faster, reproducible RWE shortens the time from hypothesis to actionable insight, compressing development timelines and conserving capital. It also aligns with evolving regulatory expectations for data provenance and methodological rigor, facilitating smoother submissions to agencies like the FDA and EMA. As payers adopt value‑based contracts, the demand for robust, real‑time evidence will only grow, making AI‑driven RWE a strategic asset for any biopharma aiming to stay ahead in a competitive market.